Robertet Valuation

Is 0NZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0NZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0NZN (€868) is trading below our estimate of fair value (€1001.75)

Significantly Below Fair Value: 0NZN is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0NZN?

Key metric: As 0NZN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0NZN. This is calculated by dividing 0NZN's market cap by their current earnings.
What is 0NZN's PE Ratio?
PE Ratio21x
Earnings€86.35m
Market Cap€1.81b

Price to Earnings Ratio vs Peers

How does 0NZN's PE Ratio compare to its peers?

The above table shows the PE ratio for 0NZN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.2x
VCT Victrex
24.4x37.8%UK£749.6m
JMAT Johnson Matthey
24x28.4%UK£2.6b
CRDA Croda International
29.7x15.1%UK£4.8b
TET Treatt
22.7x15.3%UK£256.6m
0NZN Robertet
21x8.0%€1.8b

Price-To-Earnings vs Peers: 0NZN is good value based on its Price-To-Earnings Ratio (21x) compared to the peer average (25.2x).


Price to Earnings Ratio vs Industry

How does 0NZN's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0NZN 21.0xIndustry Avg. 17.1xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0NZN is expensive based on its Price-To-Earnings Ratio (21x) compared to the European Chemicals industry average (17.9x).


Price to Earnings Ratio vs Fair Ratio

What is 0NZN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0NZN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21x
Fair PE Ratio13.3x

Price-To-Earnings vs Fair Ratio: 0NZN is expensive based on its Price-To-Earnings Ratio (21x) compared to the estimated Fair Price-To-Earnings Ratio (13.3x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0NZN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€868.00
€1,096.67
+26.3%
4.1%€1,150.00€1,040.00n/a3
Nov ’25€936.00
€1,096.67
+17.2%
4.1%€1,150.00€1,040.00n/a3
Oct ’25€951.00
€1,096.67
+15.3%
4.1%€1,150.00€1,040.00n/a3
Sep ’25€884.06
€1,096.67
+24.0%
4.1%€1,150.00€1,040.00n/a3
Aug ’25€844.00
€1,125.00
+33.3%
2.2%€1,150.00€1,100.00n/a2
Jul ’25€829.00
€1,115.00
+34.5%
1.3%€1,130.00€1,100.00n/a2
Jun ’25€868.00
€1,115.00
+28.5%
1.3%€1,130.00€1,100.00n/a2
May ’25€889.00
€1,115.00
+25.4%
1.3%€1,130.00€1,100.00n/a2
Apr ’25€793.33
€1,040.00
+31.1%
3.8%€1,080.00€1,000.00n/a2
Mar ’25€787.27
€1,040.00
+32.1%
3.8%€1,080.00€1,000.00n/a2
Feb ’25€828.00
€1,035.00
+25.0%
3.4%€1,070.00€1,000.00n/a2
Jan ’25€830.00
€1,035.00
+24.7%
3.4%€1,070.00€1,000.00n/a2
Dec ’24€755.00
€1,035.00
+37.1%
3.4%€1,070.00€1,000.00n/a2
Nov ’24€780.97
€1,106.67
+41.7%
9.5%€1,250.00€1,000.00€936.003
Oct ’24€806.97
€1,160.00
+43.7%
7.8%€1,250.00€1,070.00€951.002
Sep ’24€851.00
€1,165.00
+36.9%
7.3%€1,250.00€1,080.00€884.062
Aug ’24€821.96
€1,165.00
+41.7%
7.3%€1,250.00€1,080.00€844.002
Jul ’24€840.00
€1,165.00
+38.7%
7.3%€1,250.00€1,080.00€829.002
Jun ’24€841.00
€1,165.00
+38.5%
7.3%€1,250.00€1,080.00€868.002
May ’24€873.76
€1,165.00
+33.3%
7.3%€1,250.00€1,080.00€889.002
Apr ’24€877.00
€1,165.00
+32.8%
7.3%€1,250.00€1,080.00€793.332
Mar ’24€914.00
€1,175.00
+28.6%
6.4%€1,250.00€1,100.00€787.272
Feb ’24€861.00
€1,150.00
+33.6%
8.7%€1,250.00€1,050.00€828.002
Jan ’24€837.00
€1,150.00
+37.4%
8.7%€1,250.00€1,050.00€830.002
Dec ’23€834.00
€1,150.00
+37.9%
8.7%€1,250.00€1,050.00€755.002
Nov ’23€847.14
€1,150.00
+35.8%
8.7%€1,250.00€1,050.00€780.972

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies